Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: Evidence from cultured explants

Hepatology

Volumn 55, Issue 3, 2012, Pages 790-799

  Jourdan, Tony ^a   Demizieux, Laurent ^a   Gresti, Joseph ^a   Djaouti, Louiza ^a   Gaba, Lila ^a   Vergès, Bruno ^a   Degrace, Pascal ^a  

^a Chu   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENYLATE KINASE; ARACHIDONIC ACID N HYDROXYETHYLAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CARNITINE PALMITOYLTRANSFERASE I; CD36 ANTIGEN; ENDOCANNABINOID; FATTY ACID SYNTHASE; HIGH DENSITY LIPOPROTEIN; LIVER TRIACYLGLYCEROL LIPASE; MALONYL COENZYME A; MESSENGER RNA; RIMONABANT; SCAVENGER RECEPTOR BI; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EXPLANT; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GENE EXPRESSION; LIPID METABOLISM; LIPOGENESIS; LIVER; LIVER CELL CULTURE; MALE; MOUSE; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CARBOHYDRATE METABOLISM; CHOLESTEROL; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; FATTY LIVER; GENE EXPRESSION REGULATION; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; OBESITY; OXYGEN CONSUMPTION; PIPERIDINES; PROTEIN KINASES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RNA, MESSENGER; TISSUE CULTURE TECHNIQUES;

EID: 84857445031     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24733     Document Type: Article

References (48)

1. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-825.
2. Jamshidi N, Taylor DA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 2001; 134: 1151-1154.
3. Williams CM, Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1999; 143: 315-317.
4. Curioni C, Andre C. Rimonabant for overweight or obesity. Cochrane Database Syst Rev 2006: CD006162.
5. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007; 369: 71-77.
6. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C, et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. HEPATOLOGY 2007; 46: 122-129.
7. Poirier B, Bidouard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE, et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 2005; 7: 65-72.
8. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie P. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284: R345-R353.
9. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134.
10. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
11. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370: 1706-1713.
12. Di Marzo V, Despres JP. CB1 antagonists for obesity-what lessons have we learned from rimonabant? Nat Rev Endocrinol 2009; 5: 633-638.
13. Jourdan T, Djaouti L, Demizieux L, Gresti J, Verges B, Degrace P. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 2010; 59: 926-934.
14. Matias I, Bisogno T, Di Marzo V. Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. Int J Obes (Lond) 2006; 30( Suppl 1): S7-S12.
15. Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschop J, Caldwell C, et al. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 2008; 57: 2977-2991.
16. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI, et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008; 118: 3160-3169.
17. Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010; 120: 2953-2966.
18. Djaouti L, Jourdan T, Demizieux L, Chevrot M, Gresti J, Verges B, Degrace P. Different effects of pioglitazone and rosiglitazone on lipid metabolism in mouse cultured liver explants. Diabetes Metab Res Rev 2010; 26: 297-305.
19. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497-509.
20. Niot I, Gresti J, Boichot J, Sempore G, Durand G, Bezard J, Clouet P. Effect of dietary n-3 and n-6 polyunsaturated fatty acids on lipid-metabolizing enzymes in obese rat liver. Lipids 1994; 29: 481-489.
21. Jourdan T, Djaouti L, Demizieux L, Gresti J, Verges B, Degrace P. Liver carbohydrate and lipid metabolism of insulin-deficient mice is altered by trans-10, cis-12 conjugated linoleic acid. J Nutr 2009; 139: 1901-1907.
22. Demizieux L, Degrace P, Gresti J, Loreau O, Noel JP, Chardigny JM, et al. Conjugated linoleic acid isomers in mitochondria: evidence for an alteration of fatty acid oxidation. J Lipid Res 2002; 43: 2112-2122.
23. Degrace P, Moindrot B, Mohamed I, Gresti J, Du ZY, Chardigny JM, et al. Upregulation of liver VLDL receptor and FAT/CD36 expression in LDLR-/- apoB100/100 mice fed trans-10, cis-12 conjugated linoleic acid. J Lipid Res 2006; 47: 2647-2655.
24. Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L, Di Marzo V. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J 2001; 15: 2745-2747.
25. Mukhopadhyay B, Liu J, Osei-Hyiaman D, Godlewski G, Mukhopadhyay P, Wang L, et al. Transcriptional regulation of cannabinoid receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptor-gamma. J Biol Chem 2010; 285: 19002-19011.
26. Wu C, Okar DA, Kang J, Lange AJ. Reduction of hepatic glucose production as a therapeutic target in the treatment of diabetes. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5: 51-59.
27. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-1305.
28. Iynedjian PB, Jotterand D, Nouspikel T, Asfari M, Pilot PR. Transcriptional induction of glucokinase gene by insulin in cultured liver cells and its repression by the glucagon-cAMP system. J Biol Chem 1989; 264: 21824-21829.
29. Magnuson MA, Andreone TL, Printz RL, Koch S, Granner DK. Rat glucokinase gene: structure and regulation by insulin. Proc Natl Acad Sci U S A 1989; 86: 4838-4842.
30. Seoane J, Gomez-Foix AM, O'Doherty RM, Gomez-Ara C, Newgard CB, Guinovart JJ. Glucose 6-phosphate produced by glucokinase, but not hexokinase I, promotes the activation of hepatic glycogen synthase. J Biol Chem 1996; 271: 23756-23760.
31. Foretz M, Guichard C, Ferre P, Foufelle F. Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc Natl Acad Sci U S A 1999; 96: 12737-12742.
32. Girard J, Ferre P, Foufelle F. Mechanisms by which carbohydrates regulate expression of genes for glycolytic and lipogenic enzymes. Annu Rev Nutr 1997; 17: 325-352.
33. Krone W, Greten H. Evidence for post-transcriptional regulation by insulin of 3-hydroxy-3-methylglutaryl coenzyme A reductase and sterol synthesis in human mononuclear leucocytes. Diabetologia 1984; 26: 366-369.
34. Maitra A, LaVoie HA, Day RN, Garmey JC, Veldhuis JD. Regulation of porcine granulosa cell 3-hydroxy-3-methylglutaryl coenzyme A reductase by insulin and insulin-like growth factor I: synergism with follicle-stimulating hormone or protein kinase A agonist. Endocrinology 1995; 136: 5111-5117.
35. Shetty S, Eckhardt ER, Post SR, van der Westhuyzen DR. Phosphatidylinositol-3-kinase regulates scavenger receptor class B type I subcellular localization and selective lipid uptake in hepatocytes. Arterioscler Thromb Vasc Biol 2006; 26: 2125-2131.
36. Lambert G, Chase MB, Dugi K, Bensadoun A, Brewer HB, Jr., Santamarina-Fojo S. Hepatic lipase promotes the selective uptake of high density lipoprotein-cholesteryl esters via the scavenger receptor B1. J Lipid Res 1999; 40: 1294-1303.
37. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, Flier JS. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99: 2416-2422.
38. Perret B, Mabile L, Martinez L, Terce F, Barbaras R, Collet X. Hepatic lipase: structure/function relationship, synthesis, and regulation. J Lipid Res 2002; 43: 1163-1169.
39. Sugamura K, Sugiyama S, Fujiwara Y, Matsubara J, Akiyama E, Maeda H, et al. Cannabinoid 1 receptor blockade reduces atherosclerosis with enhances reverse cholesterol transport. J Atheroscler Thromb 2010; 17: 141-147.
40. Kashfi K, Mynatt RL, Cook GA. Hepatic carnitine palmitoyltransferase-I has two independent inhibitory binding sites for regulation of fatty acid oxidation. Biochim Biophys Acta 1994; 1212: 245-252.
41. Murthy MS, Pande SV. Malonyl-CoA binding site and the overt carnitine palmitoyltransferase activity reside on the opposite sides of the outer mitochondrial membrane. Proc Natl Acad Sci U S A 1987; 84: 378-382.
42. Brownsey RW, Boone AN, Elliott JE, Kulpa JE, Lee WM. Regulation of acetyl-CoA carboxylase. Biochem Soc Trans 2006; 34: 223-227.
43. Watanabe T, Kubota N, Ohsugi M, Kubota T, Takamoto I, Iwabu M, et al. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. J Biol Chem 2009; 284: 1803-1812.
44. Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo RA. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 1989; 84: 205-213.
45. Mukhopadhyay B, Cinar R, Yin S, Liu J, Tam J, Godlewski G, et al. Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver. Proc Natl Acad Sci U S A 2011; 108: 6323-6328.
46. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 1997; 272: 22330-22339.
47. Sim-Selley LJ, Brunk LK, Selley DE. Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur J Pharmacol 2001; 414: 135-143.
48. Esposito I, Proto MC, Gazzerro P, Laezza C, Miele C, Alberobello AT, et al. The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol 2008; 74: 1678-1686.